Calvin B Harley

Summary

Affiliation: Geron Corporation
Country: USA

Publications

  1. doi Telomerase and cancer therapeutics
    Calvin B Harley
    Geron Corporation, 230 Constitution Drive, Menlo Park, California 94025, USA
    Nat Rev Cancer 8:167-79. 2008
  2. ncbi Telomerase is not an oncogene
    Calvin B Harley
    Geron Corporation, Menlo Park, California, CA 94025, USA
    Oncogene 21:494-502. 2002
  3. ncbi Telomerase therapeutics for degenerative diseases
    Calvin B Harley
    Geron Corporation, Menlo Park, CA 94025, USA
    Curr Mol Med 5:205-11. 2005
  4. ncbi Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma
    Meta W Djojosubroto
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany
    Hepatology 42:1127-36. 2005
  5. pmc A natural product telomerase activator as part of a health maintenance program
    Calvin B Harley
    Geron Corporation, Menlo Park, California, USA
    Rejuvenation Res 14:45-56. 2011
  6. ncbi Cancer treatment by telomerase inhibitors: predictions by a kinetic model
    Igor A Sidorov
    National Cancer Institute, NCI Frederick, NIH, PO Box B, Frederick, MD 21702 1201, USA
    Math Biosci 181:209-21. 2003
  7. ncbi Cancer cell dynamics in presence of telomerase inhibitors: analysis of in vitro data
    Igor A Sidorov
    National Cancer Institute, NIH, Bldg 469, PO Box B, Frederick, MD 21702, USA
    J Theor Biol 219:225-33. 2002
  8. ncbi Adenoviral human telomerase reverse transcriptase dramatically improves ischemic wound healing without detrimental immune response in an aged rabbit model
    Jon E Mogford
    Wound Healing Research Laboratory, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Hum Gene Ther 17:651-60. 2006
  9. ncbi Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation
    Richard C Allsopp
    Beckman Center, Department of Pathology, Stanford University School of Medicine, CA, USA
    Blood 102:517-20. 2003
  10. ncbi Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells
    Richard C Allsopp
    Nat Med 9:369-71. 2003

Collaborators

Detail Information

Publications14

  1. doi Telomerase and cancer therapeutics
    Calvin B Harley
    Geron Corporation, 230 Constitution Drive, Menlo Park, California 94025, USA
    Nat Rev Cancer 8:167-79. 2008
    ..The prospect of adding telomerase-based therapies to the growing list of new anticancer products is promising, but what are the advantages and limitations of different approaches, and which patients are the most likely to respond?..
  2. ncbi Telomerase is not an oncogene
    Calvin B Harley
    Geron Corporation, Menlo Park, California, CA 94025, USA
    Oncogene 21:494-502. 2002
    ....
  3. ncbi Telomerase therapeutics for degenerative diseases
    Calvin B Harley
    Geron Corporation, Menlo Park, CA 94025, USA
    Curr Mol Med 5:205-11. 2005
    ..Thus, pharmacological activation of telomerase has significant potential for the treatment of a broad spectrum of chronic or degenerative diseases...
  4. ncbi Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma
    Meta W Djojosubroto
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany
    Hepatology 42:1127-36. 2005
    ..In addition to limiting the proliferative capacity of hepatoma, GRN163L might also increase the sensitivity of this tumor type to conventional chemotherapy...
  5. pmc A natural product telomerase activator as part of a health maintenance program
    Calvin B Harley
    Geron Corporation, Menlo Park, California, USA
    Rejuvenation Res 14:45-56. 2011
    ..Controlled randomized trials are planned to assess TA-65®-specific effects in humans...
  6. ncbi Cancer treatment by telomerase inhibitors: predictions by a kinetic model
    Igor A Sidorov
    National Cancer Institute, NCI Frederick, NIH, PO Box B, Frederick, MD 21702 1201, USA
    Math Biosci 181:209-21. 2003
    ..Size distribution of telomeres and tumor doubling times are of critical importance for the dynamics of tumor growth in presence of telomerase inhibitors...
  7. ncbi Cancer cell dynamics in presence of telomerase inhibitors: analysis of in vitro data
    Igor A Sidorov
    National Cancer Institute, NIH, Bldg 469, PO Box B, Frederick, MD 21702, USA
    J Theor Biol 219:225-33. 2002
    ..Rapidly growing cells with large telomeric DNA heterogeneity and small proliferating fractions as well as those with very short homogeneous telomeres would be the most sensitive to telomerase inhibitors...
  8. ncbi Adenoviral human telomerase reverse transcriptase dramatically improves ischemic wound healing without detrimental immune response in an aged rabbit model
    Jon E Mogford
    Wound Healing Research Laboratory, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Hum Gene Ther 17:651-60. 2006
    ..We conclude that Ad-hTERT is an effective and novel approach to treating the ischemic wounds of elderly patients...
  9. ncbi Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation
    Richard C Allsopp
    Beckman Center, Department of Pathology, Stanford University School of Medicine, CA, USA
    Blood 102:517-20. 2003
    ....
  10. ncbi Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells
    Richard C Allsopp
    Nat Med 9:369-71. 2003
  11. ncbi Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition
    Brittney Shea Herbert
    Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9039, USA
    Oncogene 24:5262-8. 2005
    ..These results suggest that the lipid-conjugated thio-phosphoramidates could be important for improved pharmacodynamics of telomerase inhibitors in cancer therapy...
  12. ncbi Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms
    Jacintha N O'Sullivan
    Department of Pathology, University of Washington, Seattle, Washington 98195 7705, USA
    Cytometry A 58:120-31. 2004
    ..Quantitative methods to assess telomere lengths are essential to understanding how telomere dynamics play a role in these processes...
  13. ncbi A novel telomerase template antagonist (GRN163) as a potential anticancer agent
    Akira Asai
    Kyowa Hakko Kogyo, Ltd, Pharmaceutical Research Institute, Shizuoka 411 8731, Japan
    Cancer Res 63:3931-9. 2003
    ..These data demonstrate that GRN163 has significant potential for additional development as an anticancer agent...
  14. ncbi The aging factor in health and disease: the promise of basic research on aging
    Robert N Butler
    International Longevity Center USA, Alliance for Health and the Future, and Department of Geriatrics, Mount Sinai Medical Center, New York, NY 10028, USA
    Aging Clin Exp Res 16:104-11; discussion 111-2. 2004